These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 15768185)

  • 21. Infliximab and surgical treatment of complex anal Crohn's disease.
    Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
    Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
    Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: treatment of perianal fistulizing Crohn's disease.
    Rutgeerts P
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():106-10. PubMed ID: 15352905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faecal diversion in the management of perianal Crohn's disease.
    Hong MK; Craig Lynch A; Bell S; Woods RJ; Keck JO; Johnston MJ; Heriot AG
    Colorectal Dis; 2011 Feb; 13(2):171-6. PubMed ID: 19863597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease.
    Cat H; Sophani I; Lemann M; Modiglani R; Solue JC
    Turk J Gastroenterol; 2003 Jun; 14(2):121-7. PubMed ID: 14614639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perianal Crohn's disease (Br J Surg 2004; 91: 801-814).
    Olaison G; Almer S; Anderson P
    Br J Surg; 2004 Oct; 91(10):1381. PubMed ID: 15382098
    [No Abstract]   [Full Text] [Related]  

  • 32. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 33. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L; Escher JC; Taminiau JA
    Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
    Tanaka T; Takahama K; Kimura T; Mizuno T; Nagasaka M; Iwata K; Nakano H; Muramatsu M; Takazoe M
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks and benefits of infliximab for the treatment of Crohn's disease.
    Siegel CA; Hur C; Korzenik JR; Gazelle GS; Sands BE
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1017-24; quiz 976. PubMed ID: 16843733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
    Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.